Eptacog Alfa

Eptacog Alfa Uses, Dosage, Side Effects, Food Interaction and all others data.

Recombinant human coagulation Factor VIIa (rFVIIa), intended for promoting hemostasis by activating the extrinsic pathway of the coagulation cascade. NovoSeven is a vitamin K-dependent glycoprotein consisting of 406 amino acid residues. Cloned and expressed in hamster kidney cells, the protein is catalytically active in a two-chain form.

Used in the treatment of bleeding episodes in hemophilia A or B. NovoSeven is recombinant Factor VIIa and, when complexed with tissue factor can activate coagulation Factor X to Factor Xa, as well as coagulation Factor IX to Factor IXa. Factor Xa, in complex with other factors, then converts prothrombin to thrombin, which leads to the formation of a hemostatic plug by converting fibrinogen to fibrin and thereby inducing local clotting.

Table Of contents

• Eptacog Alfa
• Uses
• Dosage
• Side Effect
• Precautions
• Interactions
• Uses during Pregnancy
• Uses during Breastfeeding
• Accute Overdose
• Food Interaction
• Half Life
• Volume of Distribution
• Clearance
• Interaction With other Medicine
• Contradiction
• Storage

Trade Name	Eptacog Alfa
Generic	Coagulation factor VIIa Recombinant Human
Coagulation factor VIIa Recombinant Human Other Names	Coagulation factor VIIa, Coagulation factor VIIa (recombinant), Coagulation factor VIIa (recombinant)-jncw, Eptacog alfa, Eptacog alfa (activated), rFVIIa
Type
Formula	C1972H3076N560O597S28
Weight	45079.1 Da
Groups	Approved
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Uses

Eptacog Alfa is a form of recombinant human coagulation Factor VII used to treat hemophilia A and B.

For treatment of hemorrhagic complications in hemophilia A and B.

Eptacog Alfa is also used to associated treatment for these conditions: Bleeding, Severe Bleeding

How Eptacog Alfa works

NovoSeven activates the coagulation or clotting cascade by cleaving Factor IX and Factor X, which activates them and then leads to activation of thrombin and fibrin.

Food Interaction

No interactions found.

Volume of Distribution

• 121 ± 30 mL/kg [adults]
• 153 ± 29 mL/kg [children]
• 280 to 290 mL/kg [congenital Factor VII deficiency]

Clearance

• 33 - 37 mL/h x kg [healthy]
• 1375 +/- 396 mL/hr [severe hemophilia A male children]
• 57.3 +/- 9.5 mL/hr/kg [severe hemophilia A male children]
• 2767 +/- 385 mL/hr [severe hemophilia A men]
• 37.6 +/- 13.1 mL/hr/kg [severe hemophilia A men]

Innovators Monograph

You find simplified version here Eptacog Alfa